A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer
Epping, Mirjam T.
Webster, Kaitlyn A.
Stack, Edward C.
Cantley, Lewis C.
Gerald, William L.
Pandolfi, Pier PaoloNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationLunardi, A., U. Ala, M. T. Epping, L. Salmena, J. G. Clohessy, K. A. Webster, G. Wang, et al. 2013. “A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.” Nature genetics 45 (7): 747-755. doi:10.1038/ng.2650. http://dx.doi.org/10.1038/ng.2650.
AbstractHere we report an integrated analysis that leverages data from treatment of genetic mouse models of prostate cancer along with clinical data from patients to elucidate new mechanisms of castration resistance. We show that castration counteracts tumor progression in a Pten-loss driven mouse model of prostate cancer through the induction of apoptosis and proliferation block. Conversely, this response is bypassed upon deletion of either Trp53 or Lrf together with Pten, leading to the development of castration resistant prostate cancer (CRPC). Mechanistically, the integrated acquisition of data from mouse models and patients identifies the expression patterns of XAF1-XIAP/SRD5A1 as a predictive and actionable signature for CRPC. Importantly, we show that combined inhibition of XIAP, SRD5A1, and AR pathways overcomes castration resistance. Thus, our co-clinical approach facilitates stratification of patients and the development of tailored and innovative therapeutic treatments.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11879681
- HMS Scholarly Articles